{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T07:18:19Z","timestamp":1774595899977,"version":"3.50.1"},"reference-count":168,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T00:00:00Z","timestamp":1576195200000},"content-version":"vor","delay-in-days":407,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100011307","name":"Association for Molecular Pathology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011307","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","journals.elsevierhealth.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.jmoldx.2018.07.002","type":"journal-article","created":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T16:53:34Z","timestamp":1534784014000},"page":"717-737","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms"],"prefix":"10.1016","volume":"20","author":[{"given":"Rebecca F.","family":"McClure","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark D.","family":"Ewalt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Crow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn L.","family":"Temple-Smolkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mrudula","family":"Pullambhatla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Sargent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmoldx.2018.07.002_bib1","series-title":"Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed 4, volume 2","author":"Swerdlow","year":"2017"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib3","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib4","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib5","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib6","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.cell.2009.02.009","article-title":"The spliceosome: design principles of a dynamic RNP machine","volume":"136","author":"Wahl","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ceb.2015.08.003","article-title":"Cohesin and human disease: lessons from mouse models","volume":"37","author":"Singh","year":"2015","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib8","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nrc3743","article-title":"Cohesin in cancer: chromosome segregation and beyond","volume":"14","author":"Losada","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib9","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.cell.2016.03.003","article-title":"Types of ubiquitin ligases","volume":"165","author":"Morreale","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib10","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib11","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","article-title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts","volume":"126","author":"Malcovati","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib13","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib14","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib15","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib16","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3324\/haematol.2014.118299","article-title":"Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations","volume":"100","author":"Al Assaf","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib17","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3324\/haematol.2014.107482","article-title":"Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations","volume":"99","author":"Andrikovics","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib18","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1182\/blood-2014-03-530865","article-title":"From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms","volume":"123","author":"Cazzola","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib19","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2014.57","article-title":"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib20","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib21","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1038\/leu.2014.66","article-title":"Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation","volume":"28","author":"Panagiota","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib22","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2011.40.7379","article-title":"Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes","volume":"30","author":"Bejar","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib23","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib24","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib25","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib26","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3324\/haematol.2013.085217","article-title":"Clinical and genetic predictors of prognosis in myelodysplastic syndromes","volume":"99","author":"Bejar","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib27","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1182\/blood-2008-12-194548","article-title":"Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms","volume":"113","author":"Grand","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib28","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2012-01-404863","article-title":"SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)","volume":"120","author":"Meggendorfer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib29","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood-2010-10-311019","article-title":"Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A","volume":"118","author":"Jankowska","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib30","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/leu.2011.10","article-title":"Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in 80% of patients with TET2 and EZH2 being of high prognostic relevance","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s12185-014-1670-3","article-title":"Molecular pathogenesis of atypical CML, CMML and MDS\/MPN-unclassifiable","volume":"101","author":"Zoi","year":"2015","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib32","doi-asserted-by":"crossref","first-page":"10767","DOI":"10.1038\/ncomms10767","article-title":"Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents","volume":"7","author":"Merlevede","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib33","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/leu.2015.337","article-title":"Age-related mutations and chronic myelomonocytic leukemia","volume":"30","author":"Mason","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib34","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib35","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/gcc.21960","article-title":"Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms","volume":"51","author":"Brecqueville","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib36","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib37","doi-asserted-by":"crossref","first-page":"e43090","DOI":"10.1371\/journal.pone.0043090","article-title":"Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis","volume":"7","author":"Traina","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib38","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2015.284","article-title":"Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib39","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ajh.23345","article-title":"FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"88","author":"Daver","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib40","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1309\/AJCPEI9XU8PYBCIO","article-title":"FLT3 and NPM1 mutations in myelodysplastic syndromes: frequency and potential value for predicting progression to acute myeloid leukemia","volume":"135","author":"Bains","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib41","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2010.31.1175","article-title":"Unraveling the molecular pathophysiology of myelodysplastic syndromes","volume":"29","author":"Bejar","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib42","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2141.2010.08381.x","article-title":"ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia","volume":"151","author":"Gelsi-Boyer","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib43","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2012-06-440347","article-title":"Clonal architecture of chronic myelomonocytic leukemias","volume":"121","author":"Itzykson","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib44","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib45","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/leu.2011.232","article-title":"SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts","volume":"26","author":"Visconte","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib46","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3324\/haematol.2012.072538","article-title":"High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic\/myeloproliferative neoplasms","volume":"98","author":"Jeromin","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib47","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3324\/haematol.2009.013631","article-title":"Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis","volume":"95","author":"Flach","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib48","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/leu.2013.120","article-title":"Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis","volume":"27","author":"Bros\u00e9us","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib49","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3324\/haematol.2011.053918","article-title":"Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis","volume":"97","author":"Broseus","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib50","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2005-09-3826","article-title":"Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders","volume":"107","author":"Passamonti","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib51","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib52","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort","volume":"112","author":"Beer","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib53","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib54","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/blood-2006-01-013540","article-title":"The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera","volume":"108","author":"Lippert","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib55","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","article-title":"Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study","volume":"30","author":"Hultcrantz","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib56","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/leu.2013.302","article-title":"Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms","volume":"28","author":"Tenedini","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib57","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3324\/haematol.13721","article-title":"JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis","volume":"94","author":"Guglielmelli","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib58","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib59","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.21645","article-title":"The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera","volume":"106","author":"Tefferi","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib60","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1182\/blood-2009-05-222331","article-title":"Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis","volume":"114","author":"Malcovati","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib61","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/leu.2009.141","article-title":"Mutations of ASXL1 gene in myeloproliferative neoplasms","volume":"23","author":"Carbuccia","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib62","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","article-title":"JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis","volume":"110","author":"Barosi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib63","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood-2005-08-3395","article-title":"V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis","volume":"107","author":"Campbell","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib64","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","article-title":"Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele","volume":"114","author":"Guglielmelli","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib65","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib66","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/leu.2011.161","article-title":"Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients","volume":"25","author":"Pardanani","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib67","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1182\/blood-2013-02-486050","article-title":"Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms","volume":"121","author":"Rumi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib68","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib69","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/leu.2015.4","article-title":"Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event","volume":"29","author":"Jawhar","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib70","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jaci.2009.05.003","article-title":"Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients","volume":"124","author":"Escribano","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib71","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"NEOPLASIA KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Garcia-montero","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib72","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1182\/blood-2011-12-397588","article-title":"In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells","volume":"120","author":"Soucie","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib73","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.3324\/haematol.2014.113159","article-title":"Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia","volume":"99","author":"Meggendorfer","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib74","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2007.06565.x","article-title":"Anaemia characterises patients with myelofibrosis harbouring Mpl mutation","volume":"137","author":"Guglielmelli","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib75","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/leu.2011.253","article-title":"IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F","volume":"26","author":"Tefferi","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib76","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib77","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2014-06-579466","article-title":"Recurrent ETNK1 mutations in atypical chronic myeloid leukemia","volume":"125","author":"Gambacorti-Passerini","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib78","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.leukres.2004.10.001","article-title":"Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"29","author":"Loh","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib79","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood.V126.23.907.907","article-title":"Somatic mutations in MDS patients are associated with clinical features and predict prognosis independent of the IPSS-R: analysis of combined datasets from the international working group for prognosis in MDS-molecular committee","volume":"126","author":"Bejar","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib80","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1158\/1078-0432.CCR-04-1932","article-title":"Heterogeneous patterns of CEBPalpha mutation status in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to acute myelogenous leukemia","volume":"11","author":"Shih","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib81","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.3324\/haematol.2010.021808","article-title":"Transcription factor mutations in myelodysplastic\/myeloproliferative neoplasms","volume":"95","author":"Ernst","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib82","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib83","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/leu.2010.124","article-title":"Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML","volume":"24","author":"Dicker","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib84","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1182\/blood.V122.21.2758.2758","article-title":"Prognostic impact of molecular mutations in 182 patients with myelodysplastic syndromes","volume":"122","author":"Kuendgen","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib85","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/leu.2009.48","article-title":"RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation","volume":"23","author":"Kuo","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib86","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/ng.2696","article-title":"Somatic SETBP1 mutations in myeloid malignancies","volume":"45","author":"Makishima","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib87","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bjh.12491","article-title":"Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression","volume":"163","author":"Fernandez-Mercado","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib88","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ajh.23611","article-title":"Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression","volume":"89","author":"Hou","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib89","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/leu.2013.58","article-title":"Clonal diversity of recurrently mutated genes in myelodysplastic syndromes","volume":"27","author":"Walter","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib90","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2011-09-377994","article-title":"SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value","volume":"119","author":"Patnaik","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib91","first-page":"3081","article-title":"Mutations in the spliceosomal machinery genes SRSF2, U2AF1, and ZRSR2 and response to decitabine in myelodysplastic syndrome","volume":"35","author":"Hong","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib92","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib93","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ng.2495","article-title":"Recurrent SETBP1 mutations in atypical chronic myeloid leukemia","volume":"45","author":"Piazza","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib94","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/leu.2013.35","article-title":"SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias","volume":"27","author":"Damm","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib95","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/leu.2013.97","article-title":"SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML","volume":"27","author":"Laborde","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib96","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/leu.2014.125","article-title":"ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients","volume":"28","author":"Patnaik","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib97","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/leu.2013.133","article-title":"SETBP1 mutations occur in 9% of MDS\/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations","volume":"27","author":"Meggendorfer","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib98","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1365-2141.2006.06081.x","article-title":"C-terminal nucleophosmin mutations are uncommon in chronic myeloid disorders","volume":"133","author":"Caudill","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib99","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2141.2009.07697.x","article-title":"Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia","volume":"145","author":"Gelsi-Boyer","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib100","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1038\/leu.2016.138","article-title":"Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes","volume":"30","author":"Nazha","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib101","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","article-title":"TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients","volume":"124","author":"Bejar","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib102","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1200\/JCO.2010.33.4938","article-title":"Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes","volume":"29","author":"Thol","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib103","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1182\/blood-2011-12-399337","article-title":"Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes","volume":"119","author":"Thol","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib104","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/leu.2013.269","article-title":"Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms","volume":"28","author":"Traina","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib105","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1182\/blood-2012-11-469619","article-title":"BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders","volume":"122","author":"Damm","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib106","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2011.58","article-title":"Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms","volume":"25","author":"Abdel-Wahab","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib107","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3324\/haematol.2009.011205","article-title":"TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia","volume":"94","author":"Kosmider","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib108","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib109","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1365-2141.2011.08865.x","article-title":"ASXL1 mutations in primary and secondary myelofibrosis","volume":"156","author":"Ricci","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib110","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/leu.2011.44","article-title":"Recurrent DNMT3A mutations in patients with myelodysplastic syndromes","volume":"25","author":"Walter","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib111","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/leu.2011.77","article-title":"DNMT3A mutations in myeloproliferative neoplasms","volume":"25","author":"Stegelmann","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib112","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib113","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/ng.620","article-title":"Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes","volume":"42","author":"Nikoloski","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib114","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/leu.2011.298","article-title":"Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients","volume":"26","author":"Patnaik","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib115","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/leu.2015.211","article-title":"IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression","volume":"30","author":"DiNardo","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib116","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3324\/haematol.2010.025494","article-title":"IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis","volume":"95","author":"Thol","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib117","doi-asserted-by":"crossref","first-page":"e100206","DOI":"10.1371\/journal.pone.0100206","article-title":"Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis","volume":"9","author":"Jin","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib118","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/leu.2010.52","article-title":"Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS\/myeloproliferative neoplasms","volume":"24","author":"Kosmider","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib119","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/leu.2010.113","article-title":"IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib120","doi-asserted-by":"crossref","first-page":"29","DOI":"10.14740\/jocmr2405w","article-title":"The clinical significance of IDH mutations in essential thrombocythemia and primary myelofibrosis","volume":"8","author":"Yonal-Hindilerden","year":"2016","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib121","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/leu.2010.77","article-title":"IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms","volume":"24","author":"Pardanani","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib122","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2012-05-429696","article-title":"SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival","volume":"120","author":"Lasho","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib123","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/leu.2010.163","article-title":"LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations","volume":"24","author":"Pardanani","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib124","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1182\/blood-2010-03-274704","article-title":"Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value","volume":"116","author":"Smith","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib125","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1182\/blood-2009-04-215814","article-title":"TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)","volume":"114","author":"Kosmider","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib126","doi-asserted-by":"crossref","first-page":"6153","DOI":"10.1182\/blood-2011-07-365320","article-title":"Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype","volume":"118","author":"Grossmann","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib127","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib128","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2009.47","article-title":"TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib129","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/leu.2009.37","article-title":"Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib130","first-page":"377","article-title":"Identification of novel somatic mutations in SF3B1, a gene encoding a core component of RNA splicing machinery, in myelodysplasia with ring sideroblasts and other common cancers","volume":"26","author":"Papaemmanuil","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib131","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/leu.2011.321","article-title":"SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications","volume":"26","author":"Damm","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib132","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1182\/blood-2011-12-399774","article-title":"Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis","volume":"119","author":"Makishima","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib133","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1182\/blood-2014-04-567057","article-title":"Genetic alterations of the cohesin complex genes in myeloid malignancies","volume":"124","author":"Thota","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib134","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/leu.2011.320","article-title":"SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients","volume":"26","author":"Lasho","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib135","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1182\/blood-2011-12-400994","article-title":"Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes","volume":"119","author":"Damm","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib136","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/ng.1031","article-title":"Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes","volume":"44","author":"Graubert","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib137","doi-asserted-by":"crossref","first-page":"E277","DOI":"10.1002\/ajh.23541","article-title":"Clinical implications of U2AF1 mutation in patients in myelodysplastic syndrome and its stability during disease progression","volume":"88","author":"Wu","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib138","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/ng.2731","article-title":"Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms","volume":"45","author":"Kon","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib139","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.2010.31.8576","article-title":"TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression","volume":"29","author":"J\u00e4dersten","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib140","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1046\/j.1365-2141.2001.03073.x","article-title":"International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome","volume":"115","author":"Kita-Sasai","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib141","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.celrep.2015.02.005","article-title":"Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis","volume":"10","author":"Mckerrell","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib142","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib143","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib144","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib145","doi-asserted-by":"crossref","first-page":"12484","DOI":"10.1038\/ncomms12484","article-title":"Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults","volume":"7","author":"Young","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib146","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1038\/leu.2014.73","article-title":"Haploinsufficiencyof Sf3b1 leads to compromised stem cell function but not myelodysplasia","volume":"28","author":"Matsunawa","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib147","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","article-title":"Clinical significance of somatic mutation in unexplained blood cytopenia","volume":"129","author":"Malcovati","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib148","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1182\/blood-2015-11-679167","article-title":"Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure","volume":"128","author":"Mossner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib149","doi-asserted-by":"crossref","first-page":"877","DOI":"10.6004\/jnccn.2013.0105","article-title":"The multifaceted nature of myelodysplastic syndromes: clinical, molecular, and biological prognostic features","volume":"11","author":"Greenberg","year":"2013","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib150","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2015-04-640128","article-title":"Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion","volume":"127","author":"Chesnais","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib151","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/15384047.2017.1281491","article-title":"Chronic myelomonocytic leukemia with double-mutations in DNMT3A and FLT3-ITD treated with decitabine and sorafenib","volume":"18","author":"Gu","year":"2017","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib152","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.clml.2012.11.007","article-title":"Sustained leukemia-free state and molecular response to sorafenib in a patient with chronic myelomonocytic leukemia in transformation driven by homozygous FLT3-ITD malignant hematopoiesis","volume":"13","author":"Kosmider","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib153","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/CCO.0000000000000337","article-title":"Current management of patients with chronic myelomonocytic leukemia","volume":"29","author":"Alfonso","year":"2017","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib154","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1182\/blood-2006-04-018259","article-title":"Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia","volume":"108","author":"Scott","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib155","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib156","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib157","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1182\/blood-2012-11-467662","article-title":"SRSF2 mutation is present in the hypercellular and prefibrotic stage of primary myelofibrosis","volume":"121","author":"Lehmann","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib158","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ccr.2010.10.013","article-title":"Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling","volume":"18","author":"Chen","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib159","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12943-015-0388-z","article-title":"Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms","volume":"14","author":"Pandey","year":"2015","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib160","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1182\/asheducation-2014.1.277","article-title":"Therapy for myeloproliferative neoplasms: when, which agent, and how?","volume":"2014","author":"Geyer","year":"2014","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib161","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood-2013-05-500959","article-title":"The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment","volume":"122","author":"Gotlib","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib162","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/blood-2016-10-695981","article-title":"Genomics of chronic neutrophilic leukemia","volume":"129","author":"Maxson","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib163","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/leu.2013.122","article-title":"CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib164","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib165","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/modpathol.2016.75","article-title":"Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified","volume":"29","author":"Wang","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib166","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","article-title":"Dasatinib (BMS-354825) inhibits KIT D816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis","volume":"108","author":"Shah","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib167","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/sj.onc.1206120","article-title":"Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms","volume":"22","author":"Zermati","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.jmoldx.2018.07.002_bib168","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/ejh.12043","article-title":"Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression","volume":"90","author":"Verstovsek","year":"2012","journal-title":"Eur J Haematol"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157817304099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157817304099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T11:41:36Z","timestamp":1720525296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157817304099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":168,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S1525157817304099"],"URL":"https:\/\/doi.org\/10.1016\/j.jmoldx.2018.07.002","relation":{},"ISSN":["1525-1578"],"issn-type":[{"value":"1525-1578","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms","name":"articletitle","label":"Article Title"},{"value":"The Journal of Molecular Diagnostics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmoldx.2018.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}